FDA revisits peptide restrictions as biohacking supplement risks grow

The peptide boom has moved from niche clinics and gym talk into a broader online market, and the FDA is answering with warning letters, compounding limits, and a sharper line between approved drugs and wellness-promoted shortcuts. On one side are legitimate protein-derived therapeutics such as semaglutide and tirzepatide when they are manufactured and prescribed under the drug rules. On the other are products sold online with no proof they match the safety, purity, or effectiveness of FDA-approved medicine.

That divide is not abstract. On February 26, 2025, the FDA sent a warning letter to USApeptide.com over the unlawful sale of unapproved and misbranded semaglutide and tirzepatide. On December 10, 2024, it issued another warning letter to Summit Research Peptides after reviewing peptide products for sale including semaglutide, retatrutide, cagrilintide, tirzepatide, and mazdutide. The agency also maintains a Health Fraud Product Database and a warning-letter program aimed at products making unsubstantiated claims, a signal that the online peptide marketplace has become a recurring enforcement target.

The regulatory backdrop matters because consumers are often being sold a story before they are sold a molecule. FDA says dietary supplements are regulated as food, not drugs, and that it oversees both finished supplement products and dietary ingredients under a different framework than conventional foods and drug products. In plain terms, that means the wellness aisle does not carry the same evidentiary burden as an approved prescription therapy. FDA has repeatedly warned that unapproved peptide products sold online or through wellness channels can pose serious risk because they do not carry the same assurances of safety and effectiveness as FDA-approved drugs.

Compounding has become part of the pressure point. On April 1, 2026, FDA said the national tirzepatide shortage had been resolved and reminded compounders that specific conditions must be met for compounded drugs to qualify for legal exemptions. Under FDA’s compounding rules, state-licensed physicians and pharmacists may use only certain bulk drug substances that meet statutory criteria, including substances on FDA’s bulks list or those covered by USP/NF standards, and the agency is still evaluating nominated substances case by case. That leaves little room for the idea that any peptide can simply be relabeled as a wellness product and slipped into circulation.

The evidence gap is widest where biohackers have pushed hardest. BPC-157, a 15-amino-acid synthetic peptide, has become a social-media favorite for recovery and longevity claims, yet a 2026 review found that nearly all published data came from animal studies and a single research group, with little human evidence. The broader supplement record is just as messy: one narrative review found adulterants in 14% to 50% of analyzed sports-supplement samples in some studies. That is the real consumer journey now, from glossy claims about muscle, recovery, and longevity to a market where biology, regulation, and marketing are still badly out of sync.